Literature DB >> 8339272

Chimeric EWS-FLI1 transcript in a Ewing cell line with a complex t(11;22;14) translocation.

G Bonin1, C Scamps, C Turc-Carel, M Lipinski.   

Abstract

Peripheral neuroectodermal tumors include the differentiated neuroepithelioma and the undifferentiated Ewing's tumor. Despite clinical and pathological differences, both malignancies are characterized by a t(11;22)(q24;q12) translocation which is observed in > 90% of the cases. Molecularly, the translocation is underlaid by a rearrangement between the EWS and Fli-1 genes on chromosomes 22 and 11, respectively. Because of the difficulties in the differential diagnosis between various small round cell tumors of childhood, including Ewing's tumor, a molecular diagnostic assay would be desirable. A prerequisite for predicting the reliability of such a test resides in the molecular elucidation of the peripheral neuroectodermal tumor cases which do not exhibit the prototypical translocation. We have analyzed one such case of Ewing's tumor-derived cell line with a t(11;22;14)(q24;q12;q11) translocation. An EWS-Fli-1 fusion transcript was evidenced by polymerase chain reaction amplification of a reverse transcription product obtained from total RNA. Direct sequencing was performed to demonstrate that the molecular rearrangement in this particular Ewing sample resulted in a fusion transcript similar to those observed in tumors with the prototypical translocation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8339272

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  A method for accurate detection of translocation junctions in Ewing family of tumors.

Authors:  T Morishita; M E Bolander; K Zhang; S Tamai; Y Mii; G Sarkar
Journal:  Mol Biotechnol       Date:  2001-06       Impact factor: 2.695

2.  Targeted polytherapy in small cell sarcoma and its association with doxorubicin.

Authors:  S N Dumont; D Yang; A G Dumont; D Reynoso; J-Y Blay; J C Trent
Journal:  Mol Oncol       Date:  2014-06-10       Impact factor: 6.603

3.  EWS-erg and EWS-Fli1 fusion transcripts in Ewing's sarcoma and primitive neuroectodermal tumors with variant translocations.

Authors:  M Giovannini; J A Biegel; M Serra; J Y Wang; Y H Wei; L Nycum; B S Emanuel; G A Evans
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

Review 4.  Targeted therapies for advanced Ewing sarcoma family of tumors.

Authors:  Yunyun Jiang; Joseph Ludwig; Filip Janku
Journal:  Cancer Treat Rev       Date:  2015-03-27       Impact factor: 12.111

5.  SRE elements are binding sites for the fusion protein EWS-FLI-1.

Authors:  L Magnaghi-Jaulin; H Masutani; P Robin; M Lipinski; A Harel-Bellan
Journal:  Nucleic Acids Res       Date:  1996-03-15       Impact factor: 16.971

6.  Characterization of the genomic breakpoint and chimeric transcripts in the EWS-WT1 gene fusion of desmoplastic small round cell tumor.

Authors:  W L Gerald; J Rosai; M Ladanyi
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-14       Impact factor: 11.205

7.  The RNA binding protein EWS is broadly involved in the regulation of pri-miRNA processing in mammalian cells.

Authors:  Huiwu Ouyang; Kai Zhang; Kristi Fox-Walsh; Yang Yang; Chen Zhang; Jie Huang; Hairi Li; Yu Zhou; Xiang-Dong Fu
Journal:  Nucleic Acids Res       Date:  2017-12-01       Impact factor: 16.971

8.  Antitumor profile of the PI3K inhibitor ZSTK474 in human sarcoma cell lines.

Authors:  Nachi Namatame; Naomi Tamaki; Yuya Yoshizawa; Mutsumi Okamura; Yumiko Nishimura; Kanami Yamazaki; Miwa Tanaka; Takuro Nakamura; Kentaro Semba; Takao Yamori; Shin-Ichi Yaguchi; Shingo Dan
Journal:  Oncotarget       Date:  2018-10-12

9.  Cause and consequences of genetic and epigenetic alterations in human cancer.

Authors:  B Sadikovic; K Al-Romaih; J A Squire; M Zielenska
Journal:  Curr Genomics       Date:  2008-09       Impact factor: 2.236

10.  Mouse models of sarcomas: critical tools in our understanding of the pathobiology.

Authors:  Sean M Post
Journal:  Clin Sarcoma Res       Date:  2012-10-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.